# Intellia Therapeutics

Type: Company (NTLA)

Source: GetYourBrief — https://getyourbrief.com/entity/intellia-therapeutics
Canonical HTML page: https://getyourbrief.com/entity/intellia-therapeutics

## Timeline

- **2026-02-26**: Functional Cure Declared — Medical reports confirm the patient is effectively cured of the rare disease.
- **2025-06-10**: Long-term Follow-up — B.C. patient reports zero attacks one year after single dose.
- **2024-03-15**: Phase 1/2 Results — Intellia releases early data showing significant reduction in HAE attacks.

## Recent coverage (4 stories, network-wide)

### Payoneer Leads Mid-Cap Earnings Surge as B2B Resilience Offsets Macro Volatility
2026-02-26 22:38:34 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 12

Payoneer reported robust Q4 2025 results, driven by double-digit growth in B2B volume and strategic expansion into emerging markets. The broader mid-cap landscape shows a divergence between high-growth consumer brands like Celsius and R&D-heavy biotech firms navigating a complex regulatory environment.
Full story: https://getfinancebrief.com/story/payoneer-q4-2025-earnings-analysis

### Q4 2025 Biotech Earnings: CRISPR and Radiopharma Lead Growth
2026-02-26 22:32:41 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 12

The Q4 2025 earnings reports from leading biotech and specialty pharma firms reveal a sector-wide transition toward commercial-stage CRISPR therapies and high-growth radiopharmaceuticals. Key players like Intellia and Lantheus are setting the pace for 2026, while specialty firms focus on operational efficiency and non-opioid alternatives.
Full story: https://getbiobrief.com/story/q4-2025-biotech-earnings-analysis

### Mid-Cap Biotech Earnings: Specialized Platforms Outperform in Q4 2025
2026-02-26 22:32:06 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 12

The Q4 2025 earnings cycle for mid-cap healthcare highlights a strategic shift from clinical validation to commercial execution across gene editing, radiopharmaceuticals, and digital health. While platform innovators like Intellia and Kymera advance toward pivotal milestones, commercial leaders like Lantheus and Vericel are demonstrating the durability of high-barrier therapeutic markets.
Full story: https://gethealthbrief.com/story/mid-cap-biotech-q4-2025-earnings-intelligence

### B.C. Man Cured of Rare Disease in Landmark CRISPR Gene-Editing Success
2026-02-26 11:31:59 · Sector: bio · Sentiment: Strongly positive · Impact: 9/10 · Sources: 2

A British Columbia man has been declared functionally cured of Hereditary Angioedema (HAE) following a world-first in-vivo CRISPR gene-editing treatment. The success of Intellia Therapeutics' NTLA-2002 therapy marks a pivotal shift from chronic disease management to permanent genetic correction.
Full story: https://getbiobrief.com/story/bc-man-cured-rare-disease-gene-editing-landmark

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.